Ledraxen

Enoxaparin sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous, intravenous, and haemodialysis use. It is employed to prevent deep vein thrombosis, treat pulmonary embolism, and provide anticoagulation during renal replacement therapy.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers. Ledraxen is distributed through GNH USA's global logistics network ensuring timely delivery to authorized healthcare facilities.

Ledraxen, a low molecular weight heparin, is used in clinical settings that require inhibition of clot formation.

Prevention of deep vein thrombosis: reduces the risk of clot formation in patients at risk, such as after surgery or during prolonged immobilization. Treatment of pulmonary embolism: facilitates clot resolution and prevents recurrence in patients diagnosed with embolic events in the lungs. Anticoagulation during haemodialysis: provides safe anticoagulant coverage to maintain circuit patency without excessive bleeding during renal replacement therapy.

Enoxaparin sodium may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Injection site pain or erythema - Bruising or hematoma at the injection site - Mild bleeding such as epistaxis or gum bleeding - Nausea or gastrointestinal discomfort - Headache or dizziness

Serious or Rare Side Effects: - Major bleeding, including intracranial or gastrointestinal hemorrhage - Thrombocytopenia, including heparin‑induced thrombocytopenia (HIT) - Allergic reactions such as rash, urticaria, or anaphylaxis - Skin necrosis at injection sites - Spinal or epidural hematoma following neuraxial procedures - Elevated liver enzymes or hepatic dysfunction

When using Ledraxen, clinicians should consider several precautionary measures to minimize risks and ensure safe therapy.

Renal impairment: adjust dose or monitor anti‑